Alpha Signal Monitor - Daily Market Briefing | June 12, 2026
Daily Market Research Report
June 12, 2026
Alpha Signal Monitor
Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.
Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts
Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM
This report is generated using advanced AI research capabilities with real-time market data access.
Gold ETFs: Institutional Outlook (as of June 12, 2026)
Trading Idea: Buy Rationale (TL;DR): Consensus from major houses still points to structurally higher gold into late‑2026 on central‑bank and private‑sector diversification plus an eventual easing in real yields; use GLD/IAU/BAR to add on weakness while respecting near‑term volatility. (investing.com)
Most banks highlight persistent official‑sector buying and reserve diversification, alongside policy/geopolitical uncertainty, as key pillars; near term, stronger USD and higher real yields have pressured prices, but several desks still expect a re‑acceleration into 2H26 as rates ease. (ubs.com)
Key Drivers - Reserve diversification: EM central banks expected to keep buying; UBS keeps 2026 demand near 900t. (ubs.com) - Private‑sector diversification bid (insurance against policy risk) supports higher equilibrium price. (investing.com) - Prospect of lower real yields later in 2026 improves carry for gold. (ubs.com) - Positioning/flows light after the correction, leaving room for renewed investor demand. (marketscreener.com) - Limited mine‑supply response cited by banks as prices re‑base at higher levels. (investing.com)
| Institution | Stance | Price View | Key Evidence | Last Update | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | End‑2026 target $5,400/oz. | Raised 2026‑end forecast to $5,400 citing persistent EM central‑bank and private‑sector diversification; assumes private buyers don’t liquidate in 2026. | 2026-01-22 | (investing.com) |
| Morgan Stanley | Hold | Q4‑2026 ~$4,800/oz; bull‑case ~$5,700 in 2H26. | Sees slower gains with support from rate cuts and CB/fund buying, but base case less aggressive than peers. | 2026-01-06 | (investing.com) |
| JP Morgan | Buy | 2026 average $5,243/oz; expects climb toward ~$6,000 by year‑end after H1 softness. | Cut 2026 average on weak investor interest and light ETF/futures activity but kept a bullish 2H26 path. | 2026-05-18 | (marketscreener.com) |
| Bank of America | Buy | 2026 research target $5,000/oz (avg. ~$4,400); separate strategist flagged tactical upside risk to $6,000 by spring 2026. | BofA Global Research lifted 2026 outlook to $5,000; later, Michael Hartnett highlighted a scenario for $6,000 amid bull‑market analogs. | 2026-01-23 | (investing.com) |
| Citigroup | Hold | Near‑term (0–3m) $4,000/oz; 6–12m view around $5,000/oz; notes some risk fades later in 2026. | Trimmed 3‑month target to $4,000 in June; earlier noted overlapping risks support gold now but half may fade later this year. | 2026-06-09 | (kitco.com) |
| UBS (CIO) | Buy | End‑June 2026 $5,200/oz; year‑end 2026 $5,500/oz (cut from $5,900); earlier had $6,200 for Mar/Jun/Sep 2026. | UBS CIO scaled back targets on higher yields/stronger USD but kept a constructive 2H26 path supported by CB demand and easier Fed policy. | 2026-05-27 | (ubs.com) |
| HSBC | Hold | 2026 range $3,950–$5,050/oz; year‑end $4,450/oz; 2026 average $4,587/oz. | Sees scope for H1 strength toward $5,000 followed by potential H2 correction; volatility/high dispersion stressed. | 2026-01-08 | (archive.ph) |
| Deutsche Bank | Buy | Sees gold climbing to ~$6,000/oz in 2026. | Leans on persistent investment demand as central banks and investors increase allocations to non‑USD real assets. | 2026-01-27 | (investing.com) |
Risk Considerations - Higher‑for‑longer real yields and a firmer USD could cap rallies or force deeper drawdowns. (ubs.com) - De‑escalation of geopolitical risks could unwind safe‑haven premia faster than expected. (investing.com) - If central‑bank/private diversification buyers slow or liquidate, upside targets are at risk. (investing.com) - ETF/futures demand has been weak; continued outflows would delay any rebound. (marketscreener.com) - HSBC flags a wide 2026 trading range with scope for a late‑year correction. (archive.ph)
Position for medium‑term upside via GLD/IAU/BAR with staged adds on dips; increase exposure as US real yields roll over and USD momentum fades; reassess if central‑bank demand slows materially or policy/rates surprise hawkish for longer. (ubs.com)
Stock Ratings — Big 6 Banks — Target Prices & Ratings Snapshot (as of June 12, 2026)
Compiled from primary analyst-rating pages on Benzinga for each ticker, supplemented where needed by StreetInsider, MarketBeat, TheFly (via TipRanks posts), and Investing.com when a bank’s latest action was not listed on the Benzinga page. Sources per ticker: AAPL (Benzinga), MSFT (Benzinga; GS via StreetInsider/MarketBeat/Investing.com), GOOGL (Benzinga), AMZN (Benzinga; GS via TheFly/Investing.com; BAC via MarketBeat), NVDA (Benzinga; GS via TheFly), META (Benzinga; GS via Investing.com; JPM via MarketBeat/Investing.com), TSLA (Benzinga; GS/BAC via Investing.com and press summaries), AVGO (Benzinga), TSM (Benzinga). (benzinga.com)
AAPL - Apple Inc.
Most recent updates skew positive across the six banks, led by Morgan Stanley (June 9, 2026, $360 OW) and BofA (May 26, 2026, $380 Buy). (benzinga.com)
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $320 | 2025-10-31 | Maintained Buy with PT raised to $320 on Oct 31, 2025 (older than peers). (benzinga.com) | https://www.benzinga.com/quote/AAPL/analyst-ratings |
| Morgan Stanley | Overweight | $360 | 2026-06-09 | Maintained Overweight and raised PT to $360. (benzinga.com) | https://www.benzinga.com/quote/AAPL/analyst-ratings |
| JP Morgan | Overweight | $325 | 2026-01-30 | Maintained Overweight with $325 PT (also $315 on Jan 26, 2026). (benzinga.com) | https://www.benzinga.com/quote/AAPL/analyst-ratings |
| Bank of America | Buy | $380 | 2026-05-26 | Maintained Buy; PT to $380 on May 26, 2026. (benzinga.com) | https://www.benzinga.com/quote/AAPL/analyst-ratings |
| Citigroup | Buy | $315 | 2026-01-20 | Maintained Buy; latest noted $315 on Jan 20, 2026 (also $330 on Dec 9, 2025). (benzinga.com) | https://www.benzinga.com/quote/AAPL/analyst-ratings |
| Wells Fargo | Overweight | $310 | 2026-05-01 | Maintained Overweight; PT to $310 on May 1, 2026. (benzinga.com) | https://www.benzinga.com/quote/AAPL/analyst-ratings |
Consensus View - Rating: Buy, Target Price: $335 - All six are positive; simple average PT ≈ $335 across listed banks.
MSFT - Microsoft Corp.
Coverage remains broadly bullish; Wells Fargo and Citi reiterated high-$600s/$600+ targets into 2026; Goldman most recently guided ~$600–$610. (benzinga.com)
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $610 | 2026-04-30 | Raised PT to $610 (from $600) while maintaining Buy. (streetinsider.com) | https://www.streetinsider.com/Analyst+Comments/Microsoft+(MSFT)+PT+Raised+to+$610+at+Goldman+Sachs/26398551.html |
| Morgan Stanley | Overweight | $650 | 2025-10-30 | Maintained Overweight; PT to $650. (benzinga.com) | https://www.benzinga.com/quote/MSFT/analyst-ratings |
| JP Morgan | Overweight | $575 | 2025-10-30 | Maintained Overweight; PT to $575. (benzinga.com) | https://www.benzinga.com/quote/MSFT/analyst-ratings |
| Bank of America | Buy | $500 | 2026-03-24 | Reinstated Buy with $500 PT (after Jan 26, 2026 update to $520). (benzinga.com) | https://www.benzinga.com/quote/MSFT/analyst-ratings |
| Citigroup | Buy | $620 | 2026-04-30 | Maintained Buy; PT to $620. (benzinga.com) | https://www.benzinga.com/quote/MSFT/analyst-ratings |
| Wells Fargo | Overweight | $650 | 2026-06-01 | Maintained Overweight; PT to $650 (also $625 on Apr 30, 2026). (benzinga.com) | https://www.benzinga.com/quote/MSFT/analyst-ratings |
Consensus View - Rating: Buy, Target Price: $601 - Average of listed PTs ≈ $601; 6/6 bullish (Buy/OW).
GOOGL - Alphabet Inc.
Six-bank set shows continued Buy/Overweight stances and rising PTs through 1H26. (benzinga.com)
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $375 | 2026-01-13 | Maintained Buy; PT to $375. (benzinga.com) | https://www.benzinga.com/quote/GOOGL/analyst-ratings |
| Morgan Stanley | Overweight | $375 | 2026-04-30 | Maintained Overweight; PT to $375. (benzinga.com) | https://www.benzinga.com/quote/GOOGL/analyst-ratings |
| JP Morgan | Overweight | $395 | 2026-02-05 | Maintained Overweight; PT to $395. (benzinga.com) | https://www.benzinga.com/quote/GOOGL/analyst-ratings |
| Bank of America | Buy | $370 | 2026-01-13 | Maintained Buy; PT to $370. (benzinga.com) | https://www.benzinga.com/quote/GOOGL/analyst-ratings |
| Citigroup | Buy | $447 | 2026-04-30 | Maintained Buy; PT to $447. (benzinga.com) | https://www.benzinga.com/quote/GOOGL/analyst-ratings |
| Wells Fargo | Overweight | $435 | 2026-05-20 | Maintained Overweight; PT to $435 (after upgrade in Feb 2026). (benzinga.com) | https://www.benzinga.com/quote/GOOGL/analyst-ratings |
Consensus View - Rating: Buy, Target Price: $400 - Average ≈ $400 across listed banks.
AMZN - Amazon.com Inc.
Post–Q1 2026 prints, most banks raised PTs; GS most recently to $325; BAC to $310. (benzinga.com)
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $325 | 2026-04-30 | Raised PT to $325; kept Buy. (tipranks.com) | https://www.tipranks.com/news/the-fly/amazon-com-price-target-raised-to-325-from-275-at-goldman-sachs-thefly-news |
| Morgan Stanley | Overweight | $330 | 2026-04-30 | Maintained Overweight; PT to $330. (benzinga.com) | https://www.benzinga.com/quote/AMZN/analyst-ratings |
| JP Morgan | Overweight | $330 | 2026-04-30 | Maintained Overweight; PT to $330. (benzinga.com) | https://www.benzinga.com/quote/AMZN/analyst-ratings |
| Bank of America | Buy | $310 | 2026-04-30 | Raised PT to $310; reiterated Buy (post-earnings). (marketbeat.com) | https://www.marketbeat.com/instant-alerts/amazoncom-nasdaqamzn-price-target-raised-to-31000-at-bank-of-america-2026-04-30/ |
| Citigroup | Buy | $325 | 2026-04-30 | Maintained Buy; PT to $325. (benzinga.com) | https://www.benzinga.com/quote/AMZN/analyst-ratings |
| Wells Fargo | Overweight | $312 | 2026-05-20 | Maintained Overweight; PT ~ $312. (benzinga.com) | https://www.benzinga.com/quote/AMZN/analyst-ratings |
Consensus View - Rating: Buy, Target Price: $322 - Average ≈ $322 across the six.
NVDA - NVIDIA Corp.
Following May 2026 results, banks lifted targets; BofA at $350, JPM at $280, MS at $288; GS lifted to $285. (benzinga.com)
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $285 | 2026-05-21 | Raised PT to $285; kept Buy (TheFly post via TipRanks). (tipranks.com) | https://www.tipranks.com/news/the-fly/nvidia-price-target-raised-to-285-from-250-at-goldman-sachs-thefly-news |
| Morgan Stanley | Overweight | $288 | 2026-05-21 | Maintained Overweight; PT to $288. (benzinga.com) | https://www.benzinga.com/quote/NVDA/analyst-ratings |
| JP Morgan | Overweight | $280 | 2026-05-21 | Maintained Overweight; PT to $280. (benzinga.com) | https://www.benzinga.com/quote/NVDA/analyst-ratings |
| Bank of America | Buy | $350 | 2026-05-21 | Maintained Buy; PT to $350. (benzinga.com) | https://www.benzinga.com/quote/NVDA/analyst-ratings |
| Citigroup | Buy | $300 | 2026-02-26 | Maintained Buy; PT to $300. (benzinga.com) | https://www.benzinga.com/quote/NVDA/analyst-ratings |
| Wells Fargo | Overweight | $315 | 2026-05-12 | Maintained Overweight; PT to $315. (benzinga.com) | https://www.benzinga.com/quote/NVDA/analyst-ratings |
Consensus View - Rating: Buy, Target Price: $303 - Average ≈ $303; unanimous Buy/OW.
META - Meta Platforms Inc.
JPM downgraded to Neutral with $725 on Apr 30, 2026, while GS kept Buy and ~mid‑$800s PT; WFC and MS trimmed but remain Overweight. (benzinga.com)
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $830 | 2026-05- | Most recent press noted GS trimming to ~$830 while maintaining Buy. (investing.com) | https://www.investing.com/news/analyst-ratings/goldman-sachs-lowers-meta-stock-price-target-to-830-on-capex-rise-93CH-4648172 |
| Morgan Stanley | Overweight | $775 | 2026-03-30 | Maintained Overweight; PT to $775. (benzinga.com) | https://www.benzinga.com/quote/META/analyst-ratings |
| JP Morgan | Neutral | $725 | 2026-04-30 | Downgraded OW→Neutral; cut PT to $725. (benzinga.com) | https://www.benzinga.com/quote/META/analyst-ratings |
| Bank of America | Buy | $820 | 2026-04-20 | Maintained Buy; PT to $820 (also $885 on Jan 29, 2026). (benzinga.com) | https://www.benzinga.com/quote/META/analyst-ratings |
| Citigroup | Buy | $850 | 2025-10-30 | Maintained Buy; PT to $850 (latest listed on Benzinga page). (benzinga.com) | https://www.benzinga.com/quote/META/analyst-ratings |
| Wells Fargo | Overweight | $765 | 2026-05-20 | Maintained Overweight; PT $765. (benzinga.com) | https://www.benzinga.com/quote/META/analyst-ratings |
Consensus View - Rating: Buy, Target Price: $794 - Average ≈ $794; 5/6 bullish with JPM Neutral.
TSLA - Tesla Inc.
Views remain split: JPM raised to Neutral with $475 (Jun 5, 2026) while Wells Fargo stays Underweight at $125; GS most recently around $375 Neutral; BAC resumed Buy at $460 (Mar 4, 2026). (benzinga.com)
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Neutral | $375 | 2026-05- | Recent press summarized GS Neutral, PT ~$375 (earlier $405 on Jan 29, 2026). (au.investing.com) | https://www.investing.com/news/stock-market-news/goldman-sachs-reiterates-neutral-on-tesla-stock-375-target-93CH-4379245 |
| Morgan Stanley | Equal-Weight | $415 | 2026-01-29 | Maintained Equal-Weight; PT $415 (downgraded from OW on Dec 8, 2025). (benzinga.com) | https://www.benzinga.com/quote/TSLA/analyst-ratings |
| JP Morgan | Neutral | $475 | 2026-06-05 | Upgraded Underweight→Neutral; PT to $475 on Jun 5, 2026. (benzinga.com) | https://www.benzinga.com/quote/TSLA/analyst-ratings |
| Bank of America | Buy | $460 | 2026-03-04 | Resumed/assumed coverage with Buy and $460 PT. (price-target.com) | https://price-target.com/2026/03/04/165066/ |
| Citigroup | - | - | - | No recent bank-specific TSLA entry found on Benzinga page for Citi within the last 12 months. | https://www.benzinga.com/quote/TSLA/analyst-ratings |
| Wells Fargo | Underweight | $125 | 2026-01-29 | Maintained Underweight; PT $125. (benzinga.com) | https://www.benzinga.com/quote/TSLA/analyst-ratings |
Consensus View - Rating: Hold, Target Price: $370 - Mixed set (Buy/Neutral/Hold/Sell); simple average across available PTs ≈ $370.
AVGO - Broadcom Inc.
Strongly bullish across the six; latest round (Jun 4, 2026) saw JPM to $580, BAC to $530, UBS/Mizuho/others also raised. (benzinga.com)
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $435 | 2025-11-26 | Maintained Buy; PT to $435 (latest visible on Benzinga). (benzinga.com) | https://www.benzinga.com/quote/AVGO/analyst-ratings |
| Morgan Stanley | Overweight | $485 | 2026-06-01 | Maintained Overweight; PT to $485 (also $470 on Mar 6, 2026). (benzinga.com) | https://www.benzinga.com/quote/AVGO/analyst-ratings |
| JP Morgan | Overweight | $580 | 2026-06-04 | Maintained Overweight; PT to $580. (benzinga.com) | https://www.benzinga.com/quote/AVGO/analyst-ratings |
| Bank of America | Buy | $530 | 2026-06-04 | Maintained Buy; PT to $530. (benzinga.com) | https://www.benzinga.com/quote/AVGO/analyst-ratings |
| Citigroup | Buy | $500 | 2026-05-12 | Maintained Buy; PT to $500. (benzinga.com) | https://www.benzinga.com/quote/AVGO/analyst-ratings |
| Wells Fargo | Overweight | $545 | 2026-05-14 | Maintained Overweight; PT to $545 (also $430 upgrade Jan 15, 2026). (benzinga.com) | https://www.benzinga.com/quote/AVGO/analyst-ratings |
Consensus View - Rating: Buy, Target Price: $513 - Average ≈ $513; 6/6 bullish.
TSM - TSM Corp.
Recent high-profile actions came from Barclays/Needham/DA Davidson; no recent publicly listed moves from the six U.S. banks below on Benzinga’s page. (benzinga.com)
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | - | - | - | No recent GS action found on Benzinga TSM page. | https://www.benzinga.com/quote/TSM/analyst-ratings |
| Morgan Stanley | - | - | - | No recent MS action found on Benzinga TSM page. | https://www.benzinga.com/quote/TSM/analyst-ratings |
| JP Morgan | - | - | - | No recent JPM action found on Benzinga TSM page. | https://www.benzinga.com/quote/TSM/analyst-ratings |
| Bank of America | - | - | - | No recent BAC action found on Benzinga TSM page. | https://www.benzinga.com/quote/TSM/analyst-ratings |
| Citigroup | - | - | - | No recent Citi action found on Benzinga TSM page. | https://www.benzinga.com/quote/TSM/analyst-ratings |
| Wells Fargo | - | - | - | No recent WFC action found on Benzinga TSM page. | https://www.benzinga.com/quote/TSM/analyst-ratings |
Consensus View - Insufficient recent data from the specified six banks.
Highlights
- Most bullish set: AVGO — average ≈ $513 with JPM at $580 and BAC at $530 (June 4, 2026). (benzinga.com)
- Disagreement persists on TSLA: JPM upgraded to Neutral ($475) while WFC remains at $125 Underweight; GS around $375 Neutral. (benzinga.com)
- AI leaders NVDA/MSFT continue to see clustered Buy/OW ratings with raised PTs into late May/early June 2026. (benzinga.com)
Notes on methodology: where Benzinga listed multiple entries per bank, the most recent within the last 12 months was used. Ratings terminology was harmonized for consensus (Overweight/Outperform/Positive treated as Buy; Neutral/Equal‑Weight as Hold; Underweight as Sell). Simple averages were used for consensus PTs across the six named banks only.
IPO Calendar
Timeframe: June 12, 2026 to July 12, 2026 (US equity markets)
The coming month opens with SpaceX’s record-shattering IPO (priced June 11; first trade June 12), a one-off that temporarily dominates allocations and sets the tone for follow-on issuance. Beyond SpaceX, the near-term US pipeline tilts toward healthcare/biotech (e.g., Kardigan) and software (Entrata) with several issuers likely to launch roadshows after the dust settles. SPAC issuance remains active in the background but with smaller deal sizes. Renaissance Capital notes a strengthening 2026 pipeline into June as issuers time around mega-deals. (investing.com)
Space Exploration Technologies Corp. (SpaceX) (SPCX)
- Expected listing date: June 12, 2026 (priced June 11, 2026)
- Price range: $135.00 per share (final IPO price)
- Shares offered: ~555,600,000 shares (all-primary)
- Exchange: Nasdaq
- Lead underwriters: Goldman Sachs (lead left), Morgan Stanley, J.P. Morgan, Bank of America, Citigroup, (plus additional co-managers)
- Business summary: Integrated space and AI infrastructure company with three operating segments: Space (launch/spacecraft), Connectivity (Starlink), and AI computing (including xAI/COLOSSUS data center initiatives). (sec.gov)
- Notes: Reuters reports the offering raised ~$75 billion at pricing ($135/sh), targeting a ~$1.75T market cap; trading slated for June 12 on Nasdaq under SPCX. Underwriter group reportedly includes 20+ banks with Goldman as lead left. Allocation included a large retail tranche versus typical US IPOs. (investing.com)
- Sources: SEC EDGAR S-1 and S-1/A (May 20, 2026; June 2026), Reuters (multiple SpaceX IPO reports), Axios (deal size and debut timing)
Kardigan, Inc. (KARD)
- Expected listing date: Week of June 17–21, 2026 (marketing active; expected to price mid-June)
- Price range: $14.00–$16.00 (marketing range)
- Shares offered: ~23,330,000 shares (base deal)
- Exchange: Nasdaq
- Lead underwriters: J.P. Morgan, Jefferies, Leerink Partners, TD Cowen
- Business summary: Clinical-stage biotech developing precision cardiovascular therapies. Late-stage programs include danicamtiv (genetic dilated cardiomyopathy), ataciguat (calcific aortic valve stenosis), and tonlamarsen (hepatic angiotensinogen target for acute severe hypertension). (investing.com)
- Notes: Reuters indicates a targeted IPO valuation up to ~$1.4B and gross proceeds up to ~$373M at the proposed range; timing subject to market conditions. (investing.com)
- Sources: Reuters (Kardigan IPO terms, pipeline, and banks)
Entrata, Inc. (ENT)
- Exchange: NYSE
- Lead underwriters: Goldman Sachs, J.P. Morgan, Barclays, BofA Securities, Needham & Company, Raymond James, UBS Investment Bank, Wells Fargo Securities, William Blair, KeyBanc Capital Markets, Stephens Inc., Truist Securities
- Business summary: Cloud software platform for residential property management (multifamily and adjacent housing), offering end-to-end leasing, payments, accounting, and resident experience tools; will be a “controlled company” post-IPO via Silver Lake’s voting power. (sec.gov)
- Notes: S-1 filed May 28, 2026; company has applied to list as “ENT.” No marketing range or launch date disclosed as of June 12, 2026; likely to time marketing after major June listings. (sec.gov)
- Sources: SEC EDGAR Form S-1 (May 28, 2026), Renaissance Capital coverage on filings/pipeline
IPO timing, sizes, and terms can change rapidly. Data reflect filings and reporting available as of June 12, 2026. Always confirm final prospectus/SEC effectiveness and exchange notices on pricing day.
Sources
- Stock Ratings: https://au.investing.com/news/stock-market-news/goldman-sachs-reiterates-neutral-on-tesla-stock-375-target-93CH-4379245?utm_source=openai, https://price-target.com/2026/03/04/165066/, https://price-target.com/2026/03/04/165066/?utm_source=openai, https://www.benzinga.com/quote/AAPL/analyst-ratings, https://www.benzinga.com/quote/AMZN/analyst-ratings, https://www.benzinga.com/quote/AVGO/analyst-ratings, https://www.benzinga.com/quote/GOOGL/analyst-ratings, https://www.benzinga.com/quote/GOOGL/analyst-ratings/, https://www.benzinga.com/quote/META/analyst-ratings, https://www.benzinga.com/quote/MSFT/analyst-ratings, https://www.benzinga.com/quote/MSFT/analyst-ratings/, https://www.benzinga.com/quote/NVDA/analyst-ratings, https://www.benzinga.com/quote/TSLA/analyst-ratings, https://www.benzinga.com/quote/TSM/analyst-ratings, https://www.benzinga.com/quote/avgo/analyst-ratings, https://www.benzinga.com/quote/meta/analyst-ratings/, https://www.benzinga.com/quote/nvda/analyst-ratings/, https://www.investing.com/news/analyst-ratings/goldman-sachs-lowers-meta-stock-price-target-to-830-on-capex-rise-93CH-4648172, https://www.investing.com/news/analyst-ratings/goldman-sachs-lowers-meta-stock-price-target-to-830-on-capex-rise-93CH-4648172?utm_source=openai, https://www.investing.com/news/stock-market-news/goldman-sachs-reiterates-neutral-on-tesla-stock-375-target-93CH-4379245, https://www.marketbeat.com/instant-alerts/amazoncom-nasdaqamzn-price-target-raised-to-31000-at-bank-of-america-2026-04-30/, https://www.marketbeat.com/instant-alerts/amazoncom-nasdaqamzn-price-target-raised-to-31000-at-bank-of-america-2026-04-30/?utm_source=openai, https://www.streetinsider.com/Analyst%2BComments/Microsoft%2B%28MSFT%29%2BPT%2BRaised%2Bto%2B%24610%2Bat%2BGoldman%2BSachs/26398551.html?classic=1&utm_source=openai, https://www.streetinsider.com/Analyst+Comments/Microsoft+(MSFT, https://www.tipranks.com/news/the-fly/amazon-com-price-target-raised-to-325-from-275-at-goldman-sachs-thefly-news, https://www.tipranks.com/news/the-fly/amazon-com-price-target-raised-to-325-from-275-at-goldman-sachs-thefly-news?utm_source=openai, https://www.tipranks.com/news/the-fly/nvidia-price-target-raised-to-285-from-250-at-goldman-sachs-thefly-news, https://www.tipranks.com/news/the-fly/nvidia-price-target-raised-to-285-from-250-at-goldman-sachs-thefly-news?utm_source=openai
- IPO Calendar: https://www.investing.com/news/stock-market-news/heart-drug-developer-kardigan-targets-14-billion-valuation-in-us-ipo-4737321, https://www.investing.com/news/stock-market-news/musks-spacex-prices-record-75-billion-ipo-at-135-a-share-4738207?utm_source=openai, https://www.sec.gov/Archives/edgar/data/1181412/000162828026036936/spaceexplorationtechnologi.htm?utm_source=openai, https://www.sec.gov/Archives/edgar/data/2028464/000162828026038608/0001628280-26-038608-index.htm, https://www.sec.gov/Archives/edgar/data/2028464/000162828026038608/entrata-sx1.htm
Disclaimer
This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.
Generated on: 2026-06-12 at 12:20 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.
Powered by Alpha Signal Monitor | Market Intelligence Through AI